Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OCRELIZUMAB Cause Complication associated with device? 8 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Complication associated with device have been filed in association with OCRELIZUMAB (OCREVUS). This represents 0.0% of all adverse event reports for OCRELIZUMAB.

8
Reports of Complication associated with device with OCRELIZUMAB
0.0%
of all OCRELIZUMAB reports
0
Deaths
2
Hospitalizations

How Dangerous Is Complication associated with device From OCRELIZUMAB?

Of the 8 reports, 2 (25.0%) required hospitalization, and 1 (12.5%) were considered life-threatening.

Is Complication associated with device Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OCRELIZUMAB. However, 8 reports have been filed with the FAERS database.

What Other Side Effects Does OCRELIZUMAB Cause?

Covid-19 (11,454) Fatigue (5,704) Urinary tract infection (3,618) Headache (3,036) Multiple sclerosis (2,609) Asthenia (2,509) Nasopharyngitis (2,479) Gait disturbance (2,384) Pneumonia (2,333) Pain (2,327)

What Other Drugs Cause Complication associated with device?

ETONOGESTREL (6,047) COPPER (1,083) BACLOFEN (525) TREPROSTINIL (422) EPOPROSTENOL (399) LEVONORGESTREL (344) ADALIMUMAB (269) CARBIDOPA\LEVODOPA (169) MACITENTAN (169) TEDUGLUTIDE (133)

Which OCRELIZUMAB Alternatives Have Lower Complication associated with device Risk?

OCRELIZUMAB vs OCRIPLASMIN OCRELIZUMAB vs OCTINOXATE\OCTISALATE\ZINC OCRELIZUMAB vs OCTINOXATE\OCTOCRYLENE OCRELIZUMAB vs OCTREOTIDE OCRELIZUMAB vs OCTREOTIDE\OCTREOTIDE

Related Pages

OCRELIZUMAB Full Profile All Complication associated with device Reports All Drugs Causing Complication associated with device OCRELIZUMAB Demographics